Kamada announces launch of post-marketing research program for CYTOGAM

Kamada (KMDA) announced the launch of a new post-marketing research program aimed at generating key data in support of the benefits of CYTOGAM, the Company’s Cytomegalovirus Immune Globulin, in the management of cytomegalovirus, CMV, in solid organ transplantation. The research program, developed in collaboration with leading Key Opinion Leaders, is directed at advancing CMV disease management through novel strategies focused on late-onset CMV prevention and mitigation of active CMV disease, exploring alternative dosing strategies, and investigating potential new applications of CYTOGAM. The program also includes research aimed at enhancing the understanding of CYTOGAM’s mechanism of action and its functional properties against CMV and other viruses. Health economic studies to analyze the cost burden of CMV in solid organ transplantation are also planned, along with a clinical practice study to better understand the nuances of current CMV management in lung transplantation.